Everyone in the REGAL trial had already heard the news that their leukemia was in remission. Everyone had also lived through what can happen next. Their cancer had returned at least once. After another round of treatment brought it under control, doctors offered them a chance to test an unusual idea. Could a vaccine given during remission help them live longer? REGAL study design
On November 17, drugmaker Sellas reported that patients assigned to its experimental vaccine, galinpepimut-S, lived a median of 24 months after entering the trial. The median for patients assigned to the best available care their doctors could offer was 14.7 months. The result comes from the first public account of a randomized phase 3 study in 126 people with acute myeloid leukemia, or AML. Sellas trial results
Why vaccinate during remission?
AML begins in the bone marrow, where blood cells are made. Doctors can examine a marrow sample under a microscope to see how well treatment worked. One criterion for remission is that fewer than five percent of the cells are immature cells called blasts. Even when a patient reaches that threshold, leukemia cells can remain and eventually grow numerous enough for the cancer to return. National Cancer Institute
The vaccine gives immune cells a target to look for during that window. It contains small protein fragments, called peptides, based on a protein called WT1 that leukemia cells often produce in abundance. The aim is to train a patient's T cells to recognize and attack surviving cancer cells. Because many patients' leukemia cells share this target, researchers could use the same vaccine formulation across the trial. Nobody had to wait for a vaccine tailored to their own tumor. Published study design · Memorial Sloan Kettering
What the nine-month gap tells us
A donor stem cell transplant can be an option after leukemia returns. When these patients entered REGAL, they were unable to undergo one. A random assignment determined which group they joined. Doctors could choose observation or drug treatment for the comparison group, depending on the patient. The researchers agreed in advance to analyze survival once 80 participants had died. The company says reactions at the injection site were the most common treatment-related side effect. The reported gap of 9.3 months compares the points when half of each group was still alive. An individual patient's experience could fall on either side of those medians. Trial results and methods
One question the first announcement leaves open is how long the vaccine group stayed free of leukemia before a relapse. Sellas says it will release more detailed results at a medical meeting and submit them for peer review. The vaccine remains investigational. For patients facing a second remission without a transplant option, the next evidence to watch is how much of the extra time was spent with the disease still under control. Sellas disclosure · Independent clinical perspective

